(ZBH) Zimmer Biomet Holdings - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US98956P1021
Stock: Knee, Hip, Trauma, Spine, Robotics
Total Rating 37
Risk 89
Buy Signal 0.11
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.97% |
| Yield on Cost 5y | 0.65% |
| Yield CAGR 5y | 0.00% |
| Payout Consistency | 97.0% |
| Payout Ratio | 16.6% |
| Risk 5d forecast | |
|---|---|
| Volatility | 25.1% |
| Relative Tail Risk | -9.54% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.37 |
| Alpha | -23.96 |
| Character TTM | |
|---|---|
| Beta | 0.323 |
| Beta Downside | 0.287 |
| Drawdowns 3y | |
|---|---|
| Max DD | 39.79% |
| CAGR/Max DD | -0.26 |
Description: ZBH Zimmer Biomet Holdings December 19, 2025
Zimmer Biomet Holdings Inc. (ZBH) is a global medical-technology firm that designs, manufactures and markets a broad portfolio of orthopedic and cranio-maxillofacial products, including knee and hip implants, sports-medicine devices, bone cement, and surgical robotics that aid surgeons in delivering patient-specific solutions.
In FY 2023 the company generated roughly $7.8 billion in revenue, with operating margins around 12 % and a 6 % year-over-year increase in robot-assisted procedure volumes-a key growth engine as hospitals adopt minimally invasive technologies. Core demand drivers include an aging U.S. population, rising prevalence of osteoarthritis, and Medicare’s evolving reimbursement policies that increasingly favor bundled-payment models and value-based care.
For a data-rich, quantitative deep-dive into ZBH’s valuation metrics and scenario analyses, consider reviewing its profile on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 805.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 1.08 > 1.0 |
| NWC/Revenue: 42.84% < 20% (prev 17.02%; Δ 25.82% < -1%) |
| CFO/TA 0.07 > 3% & CFO 1.69b > Net Income 805.2m |
| Net Debt (6.82b) to EBITDA (2.38b): 2.87 < 3 |
| Current Ratio: 2.43 > 1.5 & < 3 |
| Outstanding Shares: last quarter (198.8m) vs 12m ago -2.07% < -2% |
| Gross Margin: 71.44% > 18% (prev 0.72%; Δ 7072 % > 0.5%) |
| Asset Turnover: 35.44% > 50% (prev 34.97%; Δ 0.47% > 0%) |
| Interest Coverage Ratio: 4.61 > 6 (EBITDA TTM 2.38b / Interest Expense TTM 282.8m) |
Altman Z'' 4.05
| A: 0.15 (Total Current Assets 5.83b - Total Current Liabilities 2.40b) / Total Assets 23.49b |
| B: 0.49 (Retained Earnings 11.52b / Total Assets 23.49b) |
| C: 0.06 (EBIT TTM 1.30b / Avg Total Assets 22.60b) |
| D: 1.05 (Book Value of Equity 11.24b / Total Liabilities 10.72b) |
| Altman-Z'' Score: 4.05 = AA |
Beneish M -3.02
| DSRI: 1.02 (Receivables 1.60b/1.48b, Revenue 8.01b/7.60b) |
| GMI: 1.00 (GM 71.44% / 71.78%) |
| AQI: 0.97 (AQ_t 0.66 / AQ_t-1 0.68) |
| SGI: 1.05 (Revenue 8.01b / 7.60b) |
| TATA: -0.04 (NI 805.2m - CFO 1.69b) / TA 23.49b) |
| Beneish M-Score: -3.02 (Cap -4..+1) = AA |
What is the price of ZBH shares?
As of February 09, 2026, the stock is trading at USD 89.91 with a total of 1,511,703 shares traded.
Over the past week, the price has changed by +3.26%, over one month by -5.11%, over three months by +1.85% and over the past year by -11.58%.
Over the past week, the price has changed by +3.26%, over one month by -5.11%, over three months by +1.85% and over the past year by -11.58%.
Is ZBH a buy, sell or hold?
Zimmer Biomet Holdings has received a consensus analysts rating of 3.45.
Therefor, it is recommend to hold ZBH.
- StrongBuy: 5
- Buy: 6
- Hold: 16
- Sell: 1
- StrongSell: 1
What are the forecasts/targets for the ZBH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 102.7 | 14.3% |
| Analysts Target Price | 102.7 | 14.3% |
| ValueRay Target Price | 84.1 | -6.5% |
ZBH Fundamental Data Overview February 07, 2026
P/E Trailing = 22.0174
P/E Forward = 10.352
P/S = 2.1951
P/B = 1.3685
P/EG = 0.9005
Revenue TTM = 8.01b USD
EBIT TTM = 1.30b USD
EBITDA TTM = 2.38b USD
Long Term Debt = 7.51b USD (from longTermDebt, last quarter)
Short Term Debt = 600.0m USD (from shortTermDebt, last quarter)
Debt = 8.11b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.82b USD (from netDebt column, last quarter)
Enterprise Value = 24.40b USD (17.58b + Debt 8.11b - CCE 1.29b)
Interest Coverage Ratio = 4.61 (Ebit TTM 1.30b / Interest Expense TTM 282.8m)
EV/FCF = 15.24x (Enterprise Value 24.40b / FCF TTM 1.60b)
FCF Yield = 6.56% (FCF TTM 1.60b / Enterprise Value 24.40b)
FCF Margin = 19.99% (FCF TTM 1.60b / Revenue TTM 8.01b)
Net Margin = 10.05% (Net Income TTM 805.2m / Revenue TTM 8.01b)
Gross Margin = 71.44% ((Revenue TTM 8.01b - Cost of Revenue TTM 2.29b) / Revenue TTM)
Gross Margin QoQ = 72.05% (prev 71.49%)
Tobins Q-Ratio = 1.04 (Enterprise Value 24.40b / Total Assets 23.49b)
Interest Expense / Debt = 0.93% (Interest Expense 75.4m / Debt 8.11b)
Taxrate = 17.19% (48.0m / 279.2m)
NOPAT = 1.08b (EBIT 1.30b * (1 - 17.19%))
Current Ratio = 2.43 (Total Current Assets 5.83b / Total Current Liabilities 2.40b)
Debt / Equity = 0.64 (Debt 8.11b / totalStockholderEquity, last quarter 12.76b)
Debt / EBITDA = 2.87 (Net Debt 6.82b / EBITDA 2.38b)
Debt / FCF = 4.26 (Net Debt 6.82b / FCF TTM 1.60b)
Total Stockholder Equity = 12.54b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.56% (Net Income 805.2m / Total Assets 23.49b)
RoE = 6.42% (Net Income TTM 805.2m / Total Stockholder Equity 12.54b)
RoCE = 6.51% (EBIT 1.30b / Capital Employed (Equity 12.54b + L.T.Debt 7.51b))
RoIC = 5.46% (NOPAT 1.08b / Invested Capital 19.80b)
WACC = 5.11% (E(17.58b)/V(25.70b) * Re(7.11%) + D(8.11b)/V(25.70b) * Rd(0.93%) * (1-Tc(0.17)))
Discount Rate = 7.11% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -2.38%
[DCF Debug] Terminal Value 86.56% ; FCFF base≈1.46b ; Y1≈1.49b ; Y5≈1.65b
Fair Price DCF = 213.6 (EV 49.15b - Net Debt 6.82b = Equity 42.33b / Shares 198.2m; r=5.90% [WACC]; 5y FCF grow 2.13% → 2.90% )
EPS Correlation: 43.93 | EPS CAGR: -0.69% | SUE: 0.69 | # QB: 0
Revenue Correlation: 57.90 | Revenue CAGR: -0.48% | SUE: -0.89 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.91 | Chg30d=-0.013 | Revisions Net=-5 | Analysts=21
EPS next Year (2026-12-31): EPS=8.47 | Chg30d=-0.038 | Revisions Net=-5 | Growth EPS=+3.6% | Growth Revenue=+4.8%
P/E Forward = 10.352
P/S = 2.1951
P/B = 1.3685
P/EG = 0.9005
Revenue TTM = 8.01b USD
EBIT TTM = 1.30b USD
EBITDA TTM = 2.38b USD
Long Term Debt = 7.51b USD (from longTermDebt, last quarter)
Short Term Debt = 600.0m USD (from shortTermDebt, last quarter)
Debt = 8.11b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.82b USD (from netDebt column, last quarter)
Enterprise Value = 24.40b USD (17.58b + Debt 8.11b - CCE 1.29b)
Interest Coverage Ratio = 4.61 (Ebit TTM 1.30b / Interest Expense TTM 282.8m)
EV/FCF = 15.24x (Enterprise Value 24.40b / FCF TTM 1.60b)
FCF Yield = 6.56% (FCF TTM 1.60b / Enterprise Value 24.40b)
FCF Margin = 19.99% (FCF TTM 1.60b / Revenue TTM 8.01b)
Net Margin = 10.05% (Net Income TTM 805.2m / Revenue TTM 8.01b)
Gross Margin = 71.44% ((Revenue TTM 8.01b - Cost of Revenue TTM 2.29b) / Revenue TTM)
Gross Margin QoQ = 72.05% (prev 71.49%)
Tobins Q-Ratio = 1.04 (Enterprise Value 24.40b / Total Assets 23.49b)
Interest Expense / Debt = 0.93% (Interest Expense 75.4m / Debt 8.11b)
Taxrate = 17.19% (48.0m / 279.2m)
NOPAT = 1.08b (EBIT 1.30b * (1 - 17.19%))
Current Ratio = 2.43 (Total Current Assets 5.83b / Total Current Liabilities 2.40b)
Debt / Equity = 0.64 (Debt 8.11b / totalStockholderEquity, last quarter 12.76b)
Debt / EBITDA = 2.87 (Net Debt 6.82b / EBITDA 2.38b)
Debt / FCF = 4.26 (Net Debt 6.82b / FCF TTM 1.60b)
Total Stockholder Equity = 12.54b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.56% (Net Income 805.2m / Total Assets 23.49b)
RoE = 6.42% (Net Income TTM 805.2m / Total Stockholder Equity 12.54b)
RoCE = 6.51% (EBIT 1.30b / Capital Employed (Equity 12.54b + L.T.Debt 7.51b))
RoIC = 5.46% (NOPAT 1.08b / Invested Capital 19.80b)
WACC = 5.11% (E(17.58b)/V(25.70b) * Re(7.11%) + D(8.11b)/V(25.70b) * Rd(0.93%) * (1-Tc(0.17)))
Discount Rate = 7.11% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -2.38%
[DCF Debug] Terminal Value 86.56% ; FCFF base≈1.46b ; Y1≈1.49b ; Y5≈1.65b
Fair Price DCF = 213.6 (EV 49.15b - Net Debt 6.82b = Equity 42.33b / Shares 198.2m; r=5.90% [WACC]; 5y FCF grow 2.13% → 2.90% )
EPS Correlation: 43.93 | EPS CAGR: -0.69% | SUE: 0.69 | # QB: 0
Revenue Correlation: 57.90 | Revenue CAGR: -0.48% | SUE: -0.89 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.91 | Chg30d=-0.013 | Revisions Net=-5 | Analysts=21
EPS next Year (2026-12-31): EPS=8.47 | Chg30d=-0.038 | Revisions Net=-5 | Growth EPS=+3.6% | Growth Revenue=+4.8%